Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer
Andrea R. Hagemann(Gynecologic Oncology Group), Kimberly K. Leslie(University of New Mexico)
Cited by 12
Related Papers
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
|Journal of the National Comprehensive Cancer Network|2023|284
TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
|International Journal of Oncology|2014|97
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
|Journal of the National Comprehensive Cancer Network|2024|91
EGFR isoforms and gene regulation in human endometrial cancer cells
|Molecular Cancer|2010|56